{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=27",
    "query": {
      "intervention": "Placebo- C",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1834,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T11:48:49.400Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04990440",
      "title": "A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Bermekimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-02",
      "completion_date": "2022-03-09",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990440"
    },
    {
      "nct_id": "NCT07670650",
      "title": "PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)"
      ],
      "interventions": [
        {
          "name": "SAB-142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "5 Years to 40 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-09-01",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07670650"
    },
    {
      "nct_id": "NCT03204318",
      "title": "SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis Related Pain"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate placebo",
          "type": "DRUG"
        },
        {
          "name": "Relugolix placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 638,
      "start_date": "2017-12-07",
      "completion_date": "2021-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 43,
      "location_summary": "Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03204318"
    },
    {
      "nct_id": "NCT02078323",
      "title": "Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Constipation (IBS-C)"
      ],
      "interventions": [
        {
          "name": "Linaclotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 39,
      "start_date": "2014-02",
      "completion_date": "2018-07-20",
      "has_results": false,
      "last_update_posted_date": "2018-07-23",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02078323"
    },
    {
      "nct_id": "NCT01523990",
      "title": "A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "TG-2349",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiGen Biotechnology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 135,
      "start_date": "2011-10",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523990"
    },
    {
      "nct_id": "NCT02559817",
      "title": "A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Constipation"
      ],
      "interventions": [
        {
          "name": "Linaclotide Dose A",
          "type": "DRUG"
        },
        {
          "name": "Linaclotide Dose B",
          "type": "DRUG"
        },
        {
          "name": "Linaclotide Dose C",
          "type": "DRUG"
        },
        {
          "name": "Linaclotide Approved Adult Dose",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 101,
      "start_date": "2015-11-01",
      "completion_date": "2019-08-30",
      "has_results": true,
      "last_update_posted_date": "2020-12-28",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 46,
      "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559817"
    },
    {
      "nct_id": "NCT00903617",
      "title": "Study to Test GSK256073 in Patients With Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidaemias",
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "GSK256073",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Niaspan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2009-06-15",
      "completion_date": "2010-02-16",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 11,
      "location_summary": "Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Auburn",
          "state": "Maine"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903617"
    },
    {
      "nct_id": "NCT00656097",
      "title": "A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "CL184",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HRIG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo matching CL184",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 140,
      "start_date": "2008-03",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656097"
    },
    {
      "nct_id": "NCT03891524",
      "title": "A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthroplasty, Replacement, Knee"
      ],
      "interventions": [
        {
          "name": "JNJ-70033093 25 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-70033093 50 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-70033093 100 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-70033093 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1242,
      "start_date": "2019-06-17",
      "completion_date": "2021-04-06",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03891524"
    },
    {
      "nct_id": "NCT04232280",
      "title": "Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 315,
      "start_date": "2020-01-09",
      "completion_date": "2023-01-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-24T11:48:49.400Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04232280"
    }
  ]
}